| B6 | Expanding HIV-1 VL PT programs using a simple innovative technology | E-poster | Viral load and CD4 measurement |
| B6 | Improving viral load testing coverage among children and adults during the COVID-19 pandemic using a quality improvement approach at Baylor College of Medicine Children's Foundation HIV Clinic, Kampala, Uganda | E-poster | Viral load and CD4 measurement |
| B6 | A multipronged strategy to improve viral load testing coverage in Liberia | E-poster | Viral load and CD4 measurement |
| B6 | Monitoring for advanced disease in the UTT era: trends in CD4 count testing volumes among patients presenting for HIV care in South Africa | E-poster | Viral load and CD4 measurement |
| B6 | Viral load in adults switching to DTG-BASED first-line ART in Malawi and Zambia | E-poster | Viral load and CD4 measurement |
| B7 | No difference in urine tenofovir levels in patients living with HIV on unboosted vs dose-adjusted boosted tenofovir alafenamide | E-poster | ART adherence measurement |
| B7 | Effect of digital adherence tools on adherence to antiretroviral treatment among adults living with HIV in Kilimanjaro, Tanzania: a randomised controlled trial | E-poster | ART adherence measurement |
| B8 | HIV-1 drug resistance mutations in proviruses of early treated infants in Botswana | E-poster | Drug resistance testing |
| B8 | Integrase genotyping is highly effective on diverse HIV-1 non-B clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in Africa | E-poster | Drug resistance testing |
| B9 | Combination of Xpert® MTB/RIF and DetermineTM TB LAM assay improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Southwest Ethiopia | E-poster | Diagnosis of co-infections and co-morbidities |